ArticleDiscover oncology2022

Pre-clinical efficacy of CD20-targeted chimeric antigen receptor T cells for non-Hodgkin's lymphoma.

Hairuo Wen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.